JP2017532961A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532961A5
JP2017532961A5 JP2017520449A JP2017520449A JP2017532961A5 JP 2017532961 A5 JP2017532961 A5 JP 2017532961A5 JP 2017520449 A JP2017520449 A JP 2017520449A JP 2017520449 A JP2017520449 A JP 2017520449A JP 2017532961 A5 JP2017532961 A5 JP 2017532961A5
Authority
JP
Japan
Prior art keywords
smad7
composition
antisense oligonucleotide
item
ibd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017520449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532961A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/074066 external-priority patent/WO2016059239A1/en
Publication of JP2017532961A publication Critical patent/JP2017532961A/ja
Publication of JP2017532961A5 publication Critical patent/JP2017532961A5/ja
Pending legal-status Critical Current

Links

JP2017520449A 2014-10-17 2015-10-16 Smad7アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物 Pending JP2017532961A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462065598P 2014-10-17 2014-10-17
US62/065,598 2014-10-17
PCT/EP2015/074066 WO2016059239A1 (en) 2014-10-17 2015-10-16 Methods and compositions for treating a subject with a smad7 antisense oligonucleotide

Publications (2)

Publication Number Publication Date
JP2017532961A JP2017532961A (ja) 2017-11-09
JP2017532961A5 true JP2017532961A5 (cg-RX-API-DMAC7.html) 2018-11-29

Family

ID=54330761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017520449A Pending JP2017532961A (ja) 2014-10-17 2015-10-16 Smad7アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物

Country Status (12)

Country Link
US (2) US10337004B2 (cg-RX-API-DMAC7.html)
EP (1) EP3207136A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017532961A (cg-RX-API-DMAC7.html)
KR (1) KR20170069262A (cg-RX-API-DMAC7.html)
CN (1) CN107406851A (cg-RX-API-DMAC7.html)
AU (1) AU2015332624A1 (cg-RX-API-DMAC7.html)
CA (1) CA2964667A1 (cg-RX-API-DMAC7.html)
EA (1) EA201790867A1 (cg-RX-API-DMAC7.html)
IL (1) IL251717A0 (cg-RX-API-DMAC7.html)
MA (1) MA43331A (cg-RX-API-DMAC7.html)
MX (1) MX2017004973A (cg-RX-API-DMAC7.html)
WO (1) WO2016059239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
US9791442B2 (en) 2011-09-15 2017-10-17 Nogra Pharma Limited Methods of monitoring responsiveness to anti-SMAD7 therapy
CN104487574B (zh) 2012-04-18 2017-07-07 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2016147569A (ru) 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
EP3213070A2 (en) * 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
WO2018122376A1 (en) * 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
CN115552005A (zh) * 2020-04-24 2022-12-30 诺格拉制药有限公司 Smad7反义寡核苷酸(aso)的组合物及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1456380T1 (sl) 2001-11-02 2012-11-30 Giuliani Int Ltd Smad inhibitorji za zdravljenje cns bolezni
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
NZ594281A (en) * 2009-01-26 2013-09-27 Academisch Ziekenhuis Leiden Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil
JP6018506B2 (ja) * 2010-02-08 2016-11-02 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. 対立遺伝子多様体の選択的低減
US9791442B2 (en) 2011-09-15 2017-10-17 Nogra Pharma Limited Methods of monitoring responsiveness to anti-SMAD7 therapy
CN104487574B (zh) 2012-04-18 2017-07-07 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
EP2970419B8 (en) 2013-03-15 2019-12-11 Nogra Pharma Limited Methods of treating colorectal cancer
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2016147569A (ru) 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
US20170247695A1 (en) 2014-10-17 2017-08-31 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
MA41271A (fr) 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
US20180289692A1 (en) 2015-09-30 2018-10-11 Celgene Corporation Tlr modulators and methods of use
WO2017055611A2 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Similar Documents

Publication Publication Date Title
Silva et al. Long noncoding RNAs: a missing link in osteoporosis
US20190062740A1 (en) COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS
Usman et al. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics
Jenner et al. Insights into host responses against pathogens from transcriptional profiling
Jiang et al. Eradication of acute myeloid leukemia with FLT3 ligand–targeted miR-150 nanoparticles
CN102586408B (zh) 高血压易感基因Mfn2单核苷酸多态性位点rs3820189的检测方法及检测试剂盒
CN101892302B (zh) 高血压易感基因的rs2336384位点的用途及检测试剂盒
CN109414448A (zh) 用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子
FI3384049T3 (fi) Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
JP2018517704A5 (cg-RX-API-DMAC7.html)
KR20170069262A (ko) Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물
CN101892311A (zh) 高血压易感基因的单核苷酸多态性位点rs7550536的检测方法及检测试剂盒
JP6612232B2 (ja) 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
US20180263979A1 (en) Combination of raf inhibitors and aurora kinase inhibitors
JP2024515240A5 (cg-RX-API-DMAC7.html)
Chen et al. CD55 variant associated with pegylated-interferon α therapy response in HBeAg-positive chronic hepatitis B patients
CN101892297B (zh) 高血压易感基因单核苷酸多态性位点的检测方法及其试剂盒
JP2005500029A5 (cg-RX-API-DMAC7.html)
Day et al. Unsaturated fatty acid regulation of AraC/XylS transcription factors
JP2011193786A (ja) C型肝炎の治療効果を予測するためのマーカー群、検査方法及び検査用キット
JP7498448B2 (ja) SNHG12遺伝子に由来するncRNAの発現抑制剤を有効成分とするがん増殖抑制剤
CN122029281A (zh) 使用前胶原半乳糖基转移酶2 (colgalt2)抑制剂治疗骨关节炎
CN106267237A (zh) 一种治疗肝癌和代谢紊乱的基因药物
WO2025049568A1 (en) Treatment of muscle disorder with folliculin interacting protein 1 (fnip1) inhibitors and/or folliculin (flcn) inhibitors
CN121844049A (zh) 使用软骨中间层蛋白2 (cilp2)抑制剂治疗骨关节炎